References Bach MV, Coutts RT, Baker GB
L-Carnitine has been shown to decrease the level of markers of muscle damage
However, widespread use for weight management only took off between 2022 and 2024, driven by newer, more effective medications like semaglutide and tirzepatide, alongside growing media attention and expanded insurance coverage
While various GLP-1 RAs such as Semaglutide (Wegovy, Ozempic), Dulaglutide (Trulicity), Lixisenatide (Adlyxin), and Tirzepatide (Mounjaro, Zepbound) are commonly prescribed, their specific pharmacokinetics and effects on gastric motility vary, adding complexity to perioperative care (Almandoz et al
Semaglutide, liraglutide, and dulaglutide have all shown to reduce the occurrence of major cardiovascular events like heart attack, stroke, and death in patients with diabetes, while tirzepatide is currently being studied for the same